866-997-4948(US-Canada Toll Free)

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

Published By :

Technavio

Published Date : Aug 2016

Category :

Cardiovascular Devices

No. of Pages : 120

About Musculoskeletal Disorders

Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

Technavios analysts forecast the global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Johnson & Johnson
Amgen
Pfizer
F. Hoffmann-La Roche
Eli Lilly

Other prominent vendors
3SBio
AB Sciences
AbGenomics International
Ablynx
Adheron
Akron Molecules AG
Alder BioPharmaceuticals
Amgen Astellas BioPharma K.K. in Japan
Ampio Pharmaceuticals
Antares Medical Services
Astellas
AstraZeneca
Baxter
Biocad
Bioiberica
Boehringer Ingelheim
Bone Therapeutics
Can-Fite BioPharma
Celgene
Celltrion
Cellular Biomedicine
Cerapedics
ChemoCentryx
Chugai Pharmaceutical
Coherus Biosciences
Daiichi Sankyo
Dong-A ST
Edding Pharm
Eisai
Epirus
Eupraxia Pharmaceuticals
Flexion Therapeutics
Galapagos NV
Gedeon Richter
Gilead Sciences
GlaxoSmithKline
Histogenics
IBSA Institut Biochimique
iCeutica
Iltoo Pharma
Incyte
Innovative Med Concepts
Iroko Pharmaceuticals
ISTO Technologies
KaloBios Pharmaceuticals
KAN Research Institute
Kang Stem Biotech
Kitov Pharmaceuticals
Lexicon Pharmaceuticals
LG Life Sciences
MEDIPOST
Medivir
Merck
Mereo
Mesoblast
MOCHIDA PHARMACEUTICAL
MorphoSys
Morphotek
Mycenax
Neomed Institute
Novartis
Omeros
OrthoTrophix
Osteologix
OxyPharma
PFEnex
Philogen
PhytoHealth
Plexxikon
PLx Pharma
Protalex
Proximagen
Radius Health
Regeneron Pharmaceuticals
Samsung Bioepis
Samumed
Sandoz
Sanofi
SantoSolve AS
Steminent Biotherapeutics
Stempeutics Research
Taiwan Liposome Company
Takeda
Tarsa Therapeutics
Techfields Pharma
Tetec AG
TheraMAB
TiGenix
TissueGene
Tonix Pharmaceuticals
Translational Biosciences
UCB
Vericel
Vertex Pharmaceuticals
Vitaeris
Winston Laboratories
Zosano Pharma

Market driver
Tentative approval of advanced drugs
For a full, detailed list, view our report

Market challenge
Growing preference toward surgeries
For a full, detailed list, view our report

Market trend
Ongoing active clinical trials for biosimilars
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.







PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Pipeline portfolio
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation by disease type
Rheumatoid arthritis
Osteoarthritis
Osteoporosis
Psoriatic arthritis
Ankylosing spondylitis
Fibromyalgia
PART 08: Global rheumatoid arthritis drugs market
Market overview
PART 09: Global osteoarthritis drugs market
Market overview
PART 10: Global osteoporosis drugs market
Market overview
PART 11: Global ankylosing spondylitis drugs market
Market overview
PART 12: Global psoriatic arthritis drugs market
Market overview
PART 13: Global fibromyalgia drugs market
Market overview
PART 14: Market segmentation by type of molecule
Biologics
Small molecules
PART 15: Market segmentation by route of administration
Parenteral
Topical
Oral
PART 16: Geographical segmentation
Global musculoskeletal disorder therapeutics market by geography 2015-2020
Musculoskeletal disorders therapeutics market in Americas
Musculoskeletal disorders therapeutics market in EMEA
Musculoskeletal disorders therapeutics market in APAC
PART 17: Market drivers
High growth potential of mAbs
Unmet needs of therapeutics
Tentative approval of advanced drugs
Technological advancements in medical imaging
Combination therapies
PART 18: Impact of drivers
PART 19: Market challenges
Non-adherence to treatment regimen
Growing preference toward surgeries
Multiple patent expiries
PART 20: Impact of drivers and challenges
PART 21: Market trends
Focus on regenerative medicines
Ongoing active clinical trials for biosimilars
Growing focus toward abuse-resistant novel drugs
PART 22: Vendor landscape
Competitive scenario
PART 23: Key vendor analysis
AbbVie
Johnson & Johnson
Amgen
Pfizer
F. Hoffmann-La Roche
Eli Lilly
Other prominent vendors
PART 24: Appendix
List of abbreviations
PART 25: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
Exhibit 03: Impact of biologics on various sectors
Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
Exhibit 11: Patient assistance programs offered by companies
Exhibit 12: CAM therapies for rheumatoid arthritis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
Exhibit 18: Unmet medical needs with current osteoarthritis treatments
Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
Exhibit 34: Impact of drivers
Exhibit 35: Approval and patent expiries of top selling biologics
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors
Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
Exhibit 42: AbbVie: Metrics analysis
Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: Metrics analysis
Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
Exhibit 51: Amgen: Metrics analysis
Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
Exhibit 57: Pfizer: Metrics analysis
Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
Exhibit 68: Eli Lilly: Metrics analysis

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *